Ardelyx (ARDX) to Release Earnings on Thursday

Ardelyx (NASDAQ:ARDX - Get Free Report) is expected to announce its Q1 2025 earnings data after the market closes on Thursday, May 1st. Analysts expect Ardelyx to post earnings of ($0.10) per share and revenue of $79.40 million for the quarter.

Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.02 EPS for the quarter, hitting analysts' consensus estimates of $0.02. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%. The company had revenue of $116.13 million for the quarter, compared to analysts' expectations of $111.16 million. On average, analysts expect Ardelyx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ardelyx Stock Performance

ARDX stock traded up $0.10 during midday trading on Tuesday, reaching $5.45. 4,999,651 shares of the company's stock traded hands, compared to its average volume of 4,379,327. The company has a 50-day moving average price of $5.01 and a two-hundred day moving average price of $5.27. The company has a debt-to-equity ratio of 0.87, a quick ratio of 4.31 and a current ratio of 4.58. Ardelyx has a 52 week low of $4.02 and a 52 week high of $9.33. The firm has a market capitalization of $1.30 billion, a PE ratio of -34.06 and a beta of 0.81.

Analysts Set New Price Targets

ARDX has been the subject of a number of recent analyst reports. Jefferies Financial Group reduced their price target on shares of Ardelyx from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Thursday, January 2nd. BTIG Research initiated coverage on shares of Ardelyx in a research report on Tuesday, March 4th. They issued a "buy" rating and a $14.00 target price for the company. Piper Sandler upgraded shares of Ardelyx to a "hold" rating in a research report on Wednesday, March 12th. HC Wainwright reiterated a "neutral" rating and issued a $5.50 target price on shares of Ardelyx in a research report on Friday, February 21st. Finally, LADENBURG THALM/SH SH restated a "buy" rating and set a $11.00 price target on shares of Ardelyx in a research report on Friday, March 7th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Ardelyx presently has an average rating of "Moderate Buy" and a consensus target price of $10.61.

Insider Activity at Ardelyx

In other Ardelyx news, insider Laura A. Williams sold 4,941 shares of Ardelyx stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $5.62, for a total transaction of $27,768.42. Following the completion of the transaction, the insider now owns 303,804 shares in the company, valued at approximately $1,707,378.48. The trade was a 1.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Raab sold 41,666 shares of Ardelyx stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.36, for a total value of $223,329.76. Following the transaction, the chief executive officer now owns 1,108,719 shares of the company's stock, valued at $5,942,733.84. The trade was a 3.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 158,076 shares of company stock worth $823,804 over the last ninety days. 5.90% of the stock is owned by corporate insiders.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.